Medivir 2020 Annual Report published
Medivir AB announces the availability of its Annual Report for 2020 on its website. Highlights from the report include the progression of MIV-818, a proprietary drug for liver cancer, into phase Ib studies following positive phase Ia results. The company also renegotiated an agreement for birinapant, now licensed to IGM Biosciences, and successfully completed financing to strengthen its investor base. Medivir focuses on drugs targeting high unmet medical needs in cancer treatment.
- MIV-818 advanced to phase Ib study after promising phase Ia results.
- Successful renegotiation of birinapant agreement with IGM Biosciences.
- Strong financing support from existing and new institutional investors.
- None.
STOCKHOLM, April 6, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2020 now is available at the company's website: www.medivir.com.
In the spring of 2020, Medivir was able to present promising data from the phase Ia study and shortly thereafter initiate the phase Ib study with MIV-818, our proprietary and wholly owned candidate drug for liver cancer. In December, we succeeded in renegotiating the old agreement with TetraLogic for birinapant, which enabled us to sign a license agreement for birinapant with IGM Biosciences in mid-January 2021. In addition, at the beginning of 2021, we were able to carry out a much-needed financing of the company with strong support from both existing investors and new specialist investors. It is particularly gratifying that the share issues provided Medivir an ownership base with strong institutions in the lead.
This and much more can be found in Medivir's Annual Report 2020, published today at www.medivir.com .
For additional information, please contact
Yilmaz Mahshid, CEO
Telephone: +46 8 5468 3100
E-mail: yilmaz.mahshid@medivir.com
Magnus Christensen, CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com .
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medivir/r/medivir-2020-annual-report-published,c3320252
The following files are available for download:
Annual Report 2020 (PDF) | |
https://mb.cision.com/Public/652/3320252/9525b48fb42e114d.pdf | Press release (PDF) |
View original content:http://www.prnewswire.com/news-releases/medivir-2020-annual-report-published-301263018.html
SOURCE Medivir
FAQ
What are the highlights of Medivir's Annual Report for 2020?
When was the Annual Report for 2020 published by Medivir?
What progress has Medivir made with MIV-818?
Who is developing birinapant after Medivir's licensing agreement?
What does Medivir focus on in drug development?
